ArticleO&G open2025
Exploring Postpartum Use of Advance Provision of Ulipristal Acetate and Its Promotion of Reproductive Autonomy.
Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess use of advance provision of ulipristal acetate and to explore user perspectives on emergency contraception and reproductive autonomy.
methodsIn this prospective observational study, participants choosing no contraception or lower-efficacy contraception (barrier, withdrawal, or fertility awareness method) were recruited postpartum and received ulipristal acetate before hospital discharge. Surveys were completed at baseline and 6 weeks, 3 months, and 6 months postpartum. Univariate logistic regression models examined the association between ulipristal acetate use and participant demographics. Interviews were conducted at 6 weeks with early ulipristal acetate users and at 6 months with all participants, exploring topics around contraception and reproductive autonomy. Reflexivity and memo writing enhanced data collection. Interviews were inductively coded in NVivo 12 and analyzed with reflexive thematic analysis.
resultsSeventy-five participants were recruited. Of these participants, 12 (16%) reported using ulipristal acetate during the study period, with a mean±SD of 2.6±2.4 ulipristal acetate uses. Those who identified as Latinx had 5.30 greater odds of using ulipristal acetate (95% CI, 1.41-20.5,
conclusionPostpartum patients choosing lower-efficacy contraception valued advance provision of ulipristal acetate and reflected on ulipristal acetate as a user-controlled option, bolstering reproductive autonomy. Advance provision of ulipristal acetate can be a useful intervention to increase contraceptive access for postpartum patients before discharge.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.